

PATHWAY AND DISEASE MODELING

June 19-21, 2006 • The Fairmont Hotel • San Francisco, CA

EXPRESSION PROFILING DATA ANALYSIS

From Probes to Pathways

Dr. Hugh Salamon, Senior Scientist, Computational Biology, Berlex Biosciences

Identifying Nodal Involvement from Primary Tumor Tissue

Mr. Bill Worzel, Chief Technology Officer, Genetics Squared

Quantification of Nucleic Acids from Heterogeneous Clinical Samples

Dr. Philip Day, Senior Lecturer, Medicine, University of Manchester

BIOMARKER IDENTIFICATION FROM EXPRESSION DATA

Mechanistic Biomarkers - Delivering Success Beyond Correlation

Dr. Keith Elliston, President & CEO, Genstruct, Inc.

Use of Network-Based Approaches to Develop Biomarkers for Drug Development

Dr. John R. Lamb, Associate Scientific Director, Research Genetics, Rosetta InPharmatics, A wholly owned subsidiary of Merck & Co.

MODELING PATHWAY MODULATION BY DRUGS

Predictive Integrative Biology and Downstream Experimental Testing: A Synergistic Paradigm that Deciphers Complex Pathological Processes and Modes of Drug Action

Dr. Francois Iris, President & CSO, Bio-Modeling Systems

The Generation and Use of Regulatory Gene Networks in Endothelial Cells

Dr. Stephen Charnock-Jones, Co-Founder, GNI Ltd. and University Reader, Obstetrics and Gynecology, University of Cambridge

MODELING SIGNALING PATHWAYS

From Critical Pathway Identification to a Computational Model and its Application to Biomarker Identification

Dr. Birgit Schoeberl, Director, Network Biology, Merrimack Pharmaceuticals

RepairCHIP: A New Platform to Explore the Activated Pathways in Cancer

Dr. Jan Feng, Associate Professor, Chemistry, Temple University

The Current Model of the NF-kappaB Pathway: Theory Entwined with Experiments

Dr. Andre Levchenko, Assistant Professor, Biomedical Engineering, Johns Hopkins University

UNDERSTANDING CANCER MECHANISM FROM EXPRESSION DATA

Uveal Melanoma: Molecular Networks Underlying Extracellular Matrix Reorganization and Tumor Progression

Dr. Zarema Arbieva, Assistant Professor & Director, Medicine, The University of Illinois at Chicago

A Putative Signature of Chromosomal Instability Inferred from Gene-Expression

Dr. Zoltan Szallasi, Senior Research Scientist, CHIP, Children's Hospital Boston

CANCER DISEASE MODELING

A Case Study for Integration Informatics: From Data Integration and Management to Marker-Based Diagnostics Models

Mr. Robert Stanley, Vice President, Chief Technology Officer, IO Informatics

The Obsolescence of Reductionist Biology, Systems Biology Modeling and Cancer Cachexia Therapy Development Based on Emergent Patterns of Organization Rather than on Genes and Molecules

Dr. Fredric Young, Chief Scientist, Biophysics, Vicus Therapeutics, LLC

Calibrating Xenografts: Developing Virtual Tumors for Reduced Attrition

Dr. John Savin, CEO, Physiomics plc

Courtesy of San Francisco Convention & Visitor's Bureau, Photo by P. Fuszard.